SEC Form 4 · accession 0001562180-18-003666
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark A. Velleca
Officer — President and CEO · Director
Period of report
Aug 15, 2018
Accepted (ET)
Aug 17, 2018 · 2:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 15, 2018 | M | 5,000 | $3.72 | A | 14,000 | D | |
| Common StockF2 | Aug 15, 2018 | S | 2,699 | $55.3287 | D | 11,301 | D | |
| Common StockF3 | Aug 15, 2018 | S | 2,301 | $56.5171 | D | 9,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F4 | $3.72 | Aug 15, 2018 | M | 5,000 | D | — | Dec 21, 2025 | Common Stock | 5,000 | 134,433 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
- F2The price represents the weighted average price with a low of $55.10 and a high of $55.56. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 and 3 to this Form 4.
- F3The price represents the weighted average price with a low of $56.41 and a high of $57.24.
- F4The shares underlying this option vested as to 25% of the shares on December 21, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.